TY - JOUR
T1 - Characteristics of Anaplastic Oligodendrogliomas Short-Term Survivors
T2 - A POLA Network Study
AU - the POLA Network
AU - Garnier, Louis
AU - Vidal, Chrystelle
AU - Chinot, Olivier
AU - Moyal, Elisabeth Cohen Jonathan
AU - Djelad, Apolline
AU - Bronnimann, Charlotte
AU - Bekaert, Lien
AU - Taillandier, Luc
AU - Frenel, Jean Sébastien
AU - Langlois, Olivier
AU - Colin, Philippe
AU - Menei, Philippe
AU - Dhermain, Frédéric
AU - Carpentier, Catherine
AU - Gerazime, Aurélie
AU - Curtit, Elsa
AU - Figarella-Branger, Dominique
AU - Dehais, Caroline
AU - Ducray, François
N1 - Publisher Copyright:
© The Author(s) 2022. Published by Oxford University Press.
PY - 2022/5/1
Y1 - 2022/5/1
N2 - Background: Anaplastic oligodendrogliomas IDH-mutant and 1p/19q codeleted (AO) occasionally have a poor outcome. Herein we aimed at analyzing their characteristics. Methods: We retrospectively analyzed the characteristics of 44 AO patients with a cancer-specific survival <5 years (short-term survivors, STS) and compared them with those of 146 AO patients with a survival ≥5 years (classical survivors, CS) included in the POLA network. Results: Compared to CS, STS were older (P = .0001), less frequently presented with isolated seizures (P < .0001), more frequently presented with cognitive dysfunction (P < .0001), had larger tumors (P = .= .003), a higher proliferative index (P = .= .0003), and a higher number of chromosomal arm abnormalities (P = .= .02). Regarding treatment, STS less frequently underwent a surgical resection than CS (P = .= .0001) and were more frequently treated with chemotherapy alone (P = .= .009) or with radiotherapy plus temozolomide (P = .= .05). Characteristics independently associated with STS in multivariate analysis were cognitive dysfunction, a number of mitosis > 8, and the absence of tumor resection. Based on cognitive dysfunction, type of surgery, and number of mitosis, patients could be classified into groups of standard (18%) and high (62%) risk of <5 year survival. Conclusion: The present study suggests that although STS poor outcome appears to largely result from a more advanced disease at diagnosis, surgical resection may be particularly important in this population.
AB - Background: Anaplastic oligodendrogliomas IDH-mutant and 1p/19q codeleted (AO) occasionally have a poor outcome. Herein we aimed at analyzing their characteristics. Methods: We retrospectively analyzed the characteristics of 44 AO patients with a cancer-specific survival <5 years (short-term survivors, STS) and compared them with those of 146 AO patients with a survival ≥5 years (classical survivors, CS) included in the POLA network. Results: Compared to CS, STS were older (P = .0001), less frequently presented with isolated seizures (P < .0001), more frequently presented with cognitive dysfunction (P < .0001), had larger tumors (P = .= .003), a higher proliferative index (P = .= .0003), and a higher number of chromosomal arm abnormalities (P = .= .02). Regarding treatment, STS less frequently underwent a surgical resection than CS (P = .= .0001) and were more frequently treated with chemotherapy alone (P = .= .009) or with radiotherapy plus temozolomide (P = .= .05). Characteristics independently associated with STS in multivariate analysis were cognitive dysfunction, a number of mitosis > 8, and the absence of tumor resection. Based on cognitive dysfunction, type of surgery, and number of mitosis, patients could be classified into groups of standard (18%) and high (62%) risk of <5 year survival. Conclusion: The present study suggests that although STS poor outcome appears to largely result from a more advanced disease at diagnosis, surgical resection may be particularly important in this population.
KW - Karnofsky Performance Status
KW - age
KW - anaplastic oligodendroglioma
KW - chemotherapy
KW - proliferation
KW - radiotherapy
KW - seizure
KW - surgery
UR - http://www.scopus.com/inward/record.url?scp=85130003145&partnerID=8YFLogxK
U2 - 10.1093/oncolo/oyac023
DO - 10.1093/oncolo/oyac023
M3 - Article
C2 - 35522558
AN - SCOPUS:85130003145
SN - 1083-7159
VL - 27
SP - 414
EP - 423
JO - Oncologist
JF - Oncologist
IS - 5
ER -